August 22, 2014 7:48 AM ET

Biotechnology

Company Overview of EOS S.p.A.

Company Overview

EOS S.p.A. is engaged in the development of drug product candidates for the treatment of cancer. It is primarily involved in the development of Lucitanib, an oral small-molecule tyrosine kinase inhibitor that is in Phase I/II development to prevent the development of new blood vessels essential for tumor growth and to interfere with tumor growth in certain FGF-dependent malignancies. The company was founded in 2006 and is based in Milan, Italy. As of November 19, 2013, EOS S.p.A. operates as a subsidiary of Clovis Oncology, Inc.

Via Monte di Pietà n.1/A

Milan, MI 20121

Italy

Founded in 2006

Phone:

39 02 87 39 16 08

Fax:

39 02 87 39 16 17

Key Executives for EOS S.p.A.

Co-Founder
Age: 61
Co-Founder and Chief Operating Officer
Co-Founder
Age: 55
Co-Founder and Vice President of Operations
Compensation as of Fiscal Year 2014.

EOS S.p.A. Key Developments

Clovis Oncology, Inc., EOS S.p.A. - M&A Call

To discuss acquisition of EOS (Ethical Oncology Science) S.p.A.

EOS S.p.A. and Les Laboratoires Servier SAS Enters into Collaboration and License Agreement to Further Develop Eos Antitumor Drug E-3810

EOS S.p.A. and Les Laboratoires Servier SAS have sealed a collaboration and license agreement to further develop EOS’ antitumor drug E-3810. Under the terms of this agreement, EOS will receive a €45 million upfront payment, and Servier will obtain an exclusive license covering the world with the exception of the United States, Japan and China. In addition, for an undisclosed amount, EOS will receive clinical and registration milestones as well as royalties. The partnership will actively build on the promising results of the Phase I-IIa Study, especially regarding the treatment of breast cancer. E-3810 is a novel kinase inhibitor targeting efficiently both Fibroblast Growth Factor Receptor 1 (FGFR1) and Vascular Endothelial Growth Factor Receptor-1-3 (VEGFR-1-3) and this unique activity profile confers specific antitumor activity in FGFR1-dependent tumors and a strong antiangiogenic effect.

Similar Private Companies By Industry

Company Name Region
Genovax S.r.l. Europe
Tecnogen S.p.A. Europe
Siena Biotech S.p.A. Europe
Diatech s.r.l. Europe
Baxter Manufacturing S.p.A. Europe

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
November 19, 2013
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EOS S.p.A., please visit www.eosmilano.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.